John Barkett, MBA

John Barkett, MBA, discusses recent regulatory proposals to make massive health plan price files more usable.

John Barkett, MBA, discusses how health care price transparency can affect both patient out-of-pocket costs and overall health care spending.

Congress is unlikely to codify the recent executive order to lower drug pricing as other US officials negotiate new prices, John Barkett, MBA, of Berkeley Research Group, explains.

The immediate impact of the recent executive order aimed at lowering drug prices is likely low, as it may take until 2027 before actions detailed in the order can be enacted.

The executive order that President Donald Trump signed to lower drug prices could come under legal challenges by the drug industry.

The executive order signed on May 12 has some differences from a previous executive order originally signed by the Trump administration in 2020.

The new executive order contains multiple provisions if pharmaceutical companies do not offer "most-favored nation" pricing on medication.